TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11898913
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin prophylaxis
Study: 29735468
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil injection 150mg (Group B)
Study: 29735468
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil injection 200mg (Group C)
Study: 29735468
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil injection 100mg (Group A)
Study: 12871780
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum syndecan‐1 level (>212 microg/l)
Study: 12871780
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum syndecan‐1 level (≤212 microg/l)
Study: 10329064
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily)
Study: 10329064
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo tablets for simvastatin)
Study: 10329064
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo capsules for vitamins)
Study: 1929608
Drug: Indomethacin (Indo)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (Indo) 150 mg administered intravenously on days 0 to 5
Study: 1929608
Drug: Thymopentin (TP-5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP-5) administered subcutaneously on days 0, 2, 4, and Indomethacin
Study: 2580177
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times a day
Study: 2580177
Drug: Hydrochlorothiazide 15
Normalized name: hydrochlorothiazide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 15 mg three times a day
Study: 6753893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and hydrochlorothiazide
Study: 23715641
Drug: Jitai tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablets
Study: 26096461
Drug: Jitai tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablets and Placebo
Study: 24259652
Drug: LWD +
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LWD + CMM (Living Well With a Disability + Collaborative Medication Management)
Study: 11236936
Drug: DAT (daunomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating methotrexate (MTX) and L-asparaginase (L-asp)
Study: 11236936
Drug: DAT/MTX/L-asp regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAT/MTX/L-asp regimen
Study: 9633704
Drug: GM1 ganglioside
Normalized name: Porcine GM1 ganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 ganglioside treatment (1,000 mg IV infusion followed by 200 mg/day subcutaneously for 16 weeks)
Study: 7541258
Drug: octreotide 0.2
Normalized name: octreotide 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide 0.2 mg
Study: 7541258
Drug: octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide 0.1 mg
Study: 3291150
Drug: Sotalol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol therapy starting with 40 mg and increasing to 120 mg, followed by the maximal dose tolerated every 6 hours for 72 hours
Study: 18664154
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no treatment)
Study: 30343858
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (20 mg methylprednisolone acetate)
Study: 28156011
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of LY2979165 (20-150 mg)
Study: 28156011
Drug: Multiple once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple once-daily doses of LY2979165 (20-400 mg)
Study: 25681277
Drug: AZD5069 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 50 mg bid
Study: 25681277
Drug: AZD5069 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 80 mg bid
Study: 23441793
Drug: Nanotite (N)
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanotite (N) implants
Study: 23441793
Drug: Osseotite (O)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osseotite (O) implants
Study: 10784627
Drug: Mitoxantrone, etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone, etoposide, and cyclosporine (MEC) therapy: mitoxantrone 6 mg/m2/d for 5 days, etoposide 60 mg/m2/d for 5 days, and CSA 10 mg/kg for 2 hours followed by 30 mg/kg/d as a continuous infusion for 98 hours.
Study: 10784627
Drug: Cyclosporine (CSA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSA) levels greater than 2,400 ng/mL.
Study: 10784627
Drug: Toxicities associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicities associated with MEC therapy.
Study: 8895285
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 500 micrograms
Study: 6386512
Drug: Sustained-release terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline, 7.5 mg 2 times/day
Study: 6386512
Drug: Ordinary salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ordinary salbutamol tablets, 4 mg 3 times/day
Study: 31180829
Drug: nBETTER therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nBETTER therapy (EEG-based MI-BCI with visual feedback)
Study: 31180829
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm therapy (SAT)
Study: 29335328
Drug: 10 000
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 000 steps per day prescription for 10 weeks
Study: 25154607
Drug: Udenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil (100 mg daily for three months)
Study: 23713743
Drug: Remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3 ng/mL
Study: 24815199
Drug: Methylnaltrexone 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 0.15 mg/kg
Study: 20090354
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) interventions
Study: 9193380
Drug: alpha-tocopherol and
Normalized name: Alpha-tocopherol and selenium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol and beta-carotene (50 mg/day and 20 mg/day respectively)
Study: 8194434
Drug: daily‐aspirin‐treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily‐aspirin‐treated group (aspirin, 300mg, once everyday)
Study: 8194434
Drug: intermittent‐aspirin‐treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent‐aspirin‐treated group (aspirin, 300mg, once every three days)
Study: 8194434
Drug: non‐aspirin‐treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: non‐aspirin‐treated group
Study: 8636743
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (100 mg/m2)
Study: 3517243
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (20 mg/m2) and chlorambucil
Study: 29708829
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg i.m. every 10 weeks)
Study: 24530176
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs)
Study: 24530176
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (target systolic blood pressure <180 mm Hg within 6 h of onset of ICH)
Study: 23713578
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment
Study: 18412023
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg capsules
Study: 12590029
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg daily plus morphine
Study: 12590029
Drug: Valdecoxib 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 80 mg daily plus morphine
Study: 12590029
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus morphine
Study: 1283088
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (two cycles of cisplatin, bleomycin, vindesine, mitomycin C)
Study: 1283088
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (three cycles of cisplatin, 5-fluorouracil continuous infusion, and vindesine)
Study: 1283088
Drug: Chemotherapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (both regimens)
Study: 26730446
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release guanfacine hydrochloride (1-6 mg)
Study: 24691730
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (control) for 14 days
Study: 20522709
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) with PSC‐833 (ADEP)
Study: 20522709
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) without PSC‐833 (ADE)
Study: 17999333
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (50 g day(‐1)) treatment with low-protein diet (LPD) (<40 g day(‐1)) in group A
Study: 17999333
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (50 g day(‐1)), iron (ferrous sulphate, 200 mg day(‐1)), and folic acid (5 mg day(‐1)) treatment in group B
Study: 17999333
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (50 g day(‐1)) treatment in normal volunteers (group D)
Study: 17999333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C): CRF patients under LPD and iron and folic acid treatment
Study: 22587481
Drug: DPSGC 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 25 mg
Study: 11718157
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 every three weeks)
Study: 9863072
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) supplement (1 mg orally on the second day of hospitalization)
Study: 7887118
Drug: Edrophonium (EDR)
DrugBank: Edrophonium (DB01010)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Edrophonium (EDR) 0.5 mg kg‐1 + atropine (ATR) 0.007 mg kg‐1
Study: 7887118
Drug: Neostigmine (NST)
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine (NST) 0.04 mg kg‐1 + glycopyrrolate (GLY) 0.008 mg kg‐1
Study: 3394630
Drug: Known predictors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Known predictors of arrhythmias (including cardiac risk, age, beta-blocker agents)
Study: 31506292
Drug: Selonsertib (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib (18 mg)
Study: 31506292
Drug: Selonsertib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib (2 mg)
Study: 31506292
Drug: Selonsertib (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib (6 mg)
Study: 28834453
Drug: Intravesical rAd-IFNα/Syn3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical rAd-IFNα/Syn3 (1 × 10^11 vp/mL)
Study: 28834453
Drug: Intravesical rAd-IFNα/Syn3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical rAd-IFNα/Syn3 (3 × 10^11 vp/mL)
Study: 18155445
Drug: Adjunctive topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive topiramate (TPM)
Study: 22277179
Drug: Conventional diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretic (CD) therapy
Study: 17456217
Drug: Topical fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluticasone propionate (FP) 100 microg daily
Study: 17456217
Drug: Topical fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluticasone propionate (FP) 400 microg daily
Study: 12172896
Drug: Skin protection
Normalized name: NeutrapHor 1% Skin Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin protection measures (SP), no specific dosage or duration mentioned
Study: 12172896
Drug: Ultraviolet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet B (UVB) hardening, no specific dosage or duration mentioned
Study: 10213261
Drug: Albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol delivered by metered dose inhaler (MDI) and spacer
Study: 10213261
Drug: Albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol delivered by low-flow nebulizer (NEB)
Study: 7794851
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dydrogesterone
Study: 1791775
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dydrogesterone
Study: 7794851
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dydrogesterone
Study: 1791775
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dydrogesterone
Study: 7794851
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 10 mg dydrogesterone
Study: 1977371
Drug: Prednisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (80 mg/d orally for 5 days)
Study: 31934897
Drug: Tenapanor 50
Normalized name: tenapanor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 50 mg b.i.d.
Study: 28244495
Drug: Tenapanor 20
Normalized name: tenapanor 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 20 mg b.i.d.
Study: 28244495
Drug: Tenapanor 5
Normalized name: tenapanor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 5 mg b.i.d.
Study: 22871173
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral presentations
Study: 19720797
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor therapy in Pro/Pro homozygotes
Study: 19720797
Drug: Non-ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACE inhibitor therapy in Pro/Pro homozygotes
Study: 11464180
Drug: Micronized isotretinoin
Normalized name: Micronized ISOtretinoin 8 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized isotretinoin (0.4 mg/kg per day, fasted)
Study: 11464180
Drug: Standard isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard isotretinoin (1.0 mg/kg per day, fed, in two divided doses)
Study: 26152132
Drug: Selexipag 1,600
Normalized name: selexipag 1,600 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag 1,600 μg b.i.d. (1 x 1,600 μg tablet)
Study: 26152132
Drug: Selexipag 1,600
Normalized name: selexipag 1,600 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag 1,600 μg b.i.d. (8 x 200 μg tablets)
Study: 26846550
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg)
Study: 11239724
Drug: Day drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day drug abuse treatment
Study: 11239724
Drug: Residential drug
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential drug abuse treatment
Study: 2498105
Drug: Isosorbide‐5‐mononitrate 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate 40 mg
Study: 26014444
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (UFH) bolus (100 U/kg)
Study: 20957515
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fluoxetine and CBT (COMB)
Study: 14755377
Drug: Pre-treatment MM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment MM group (serum IL-16 level)
Study: 14755377
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with high IL-16 levels (>430 pg/ml)
Study: 14755377
Drug: Post-treatment MM
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment MM group (after chemotherapy)
Study: 14755377
Drug: Pre-treatment MM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment MM group (correlation with alpha1AT and IL-6)
Study: 9151629
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine spray, twice daily for 30 days
Study: 9151629
Drug: 0.06% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% chlorhexidine spray, twice daily for 30 days
Study: 1407193
Drug: Prophylactic surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic surfactant administration (n = 42)
Study: 1407193
Drug: Therapeutic surfactant
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic surfactant administration (n = 39)
Study: 4004197
Drug: Ceftriaxone (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (once-daily intramuscular injection) for a mean of 4.0 days
Study: 4004197
Drug: Ceftriaxone (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (once-daily intramuscular injection)
Study: 26000668
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg transmucous-buccal acetaminophen (B-APAP)
Study: 26000668
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous acetaminophen (iv-APAP)
Study: 21709061
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg thrice per day)
Study: 19843490
Drug: MgV solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgV solution 500 mg
Study: 19843490
Drug: MgV suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgV suspension 500 mg
Study: 19843490
Drug: MgV enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgV enteric-coated tablets 500 mg
Study: 16915900
Drug: Induction dose
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose of ketamine (6 mg/kg)
Study: 16915900
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ketamine (3 mg/kg)
Study: 11581108
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose depot antipsychotic
Study: 11580001
Drug: Depot antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot antipsychotics
Study: 8164297
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of wheat bran (WB)
Study: 8164297
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of wheat bran (WB)
Study: 8164297
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of vegetable fiber (VF)
Study: 8164297
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of vegetable fiber (VF)
Study: 8164297
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of fiber (control)
Study: 28528342
Drug: Nutricosmeceutical containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutricosmeceutical containing collagen bioactive peptides and antioxidants (50 mL daily)
Study: 28528342
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mL daily)
Study: 23220477
Drug: Acetaminophen (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4.0 g/day; n = 11)
Study: 23220477
Drug: Ibuprofen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1.2 g/day; n = 13)
Study: 25090744
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.6 mg/kg alone
Study: 25090744
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.6 mg/kg with nitrous oxide-oxygen inhalation
Study: 9398709
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with insulin